COVID-19-Associated Mucormycosis (CAM): Case-Series and Global
Analysis of Mortality Risk Factors

J 2021

COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors

RIAD, Abanoub, Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER et. al.

Základní údaje

Originální název

COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors

Autoři

RIAD, Abanoub (818 Egypt, garant, domácí), Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER, Yossef MANSY, Islam KASSEM, Amira Bisher KASSEM, Hans-Peter HOWALDT, Miloslav KLUGAR (203 Česká republika, domácí) a Sameh ATTIA

Vydání

Journal of Fungi, Basel, MDPI, 2021, 2309-608X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10612 Mycology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.724

Kód RIV

RIV/00216224:14110/21:00122538

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/jof7100837

UT WoS

000715320700001

Klíčová slova anglicky

co-infection; COVID-19; cross-infection; Mucorales; mucormycosis; mycoses; review; Rhizopus; risk factors; steroids

Štítky

14110525, 14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 12. 2021 09:21, Mgr. Tereza Miškechová

Anotace

V originále

Background: Since the novel coronavirus disease (COVID-19) outbreak, the cases of COVID-19 co-infections have been increasingly reported worldwide. Mucormycosis, an opportunistic fungal infection caused by members of the Mucorales order, had been frequently isolated in severely and critically ill COVID-19 patients. Methods: Initially, the anamnestic, clinical, and paraclinical features of seven COVID-19-associated mucormycosis (CAM) cases from Egypt were thoroughly reported. Subsequently, an extensive review of the literature was carried out to describe the characteristics of CAM cases globally, aiming to explore the potential risk factors of mortality in CAM patients. Results: Out of the seven reported patients in the case series, five (71.4%) were males, six (85.7%) had diabetes mellitus, and three (42.9%) had cardiovascular disease. All patients exhibited various forms of facial deformities under the computed tomography scanning, and two of them tested positive for Mucorales using the polymerase chain reaction (PCR) testing. Liposomal amphotericin B (LAmB) was prescribed to all cases, and none of them died until the end of the follow-up. On reviewing the literature, 191 cases were reported worldwide, of which 74.4% were males, 83.2% were from low-middle income countries, and 51.4% were aged 55 years old or below. Diabetes mellitus (79.1%), chronic hypertension (30%), and renal disease/failure (13.6%) were the most common medical comorbidities, while steroids (64.5%) were the most frequently prescribed medication for COVID-19, followed by Remdesivir (18.2%), antibiotics (12.7%), and Tocilizumab (5.5%). Conclusions: As the majority of the included studies were observational studies, the obtained evidence needs to be interpreted carefully. Diabetes, steroids, and Remdesivir were not associated with increased mortality risk, thus confirming that steroids used to manage severe and critical COVID-19 patients should not be discontinued. Lung involvement, bilateral manifestation, and Rhizopus isolation were associated with increased mortality risk, thus confirming that proactive screening is imperative, especially for critically ill patients. Finally, surgical management and antimycotic medications, e.g., amphotericin B and posaconazole, were associated with decreased mortality risk, thus confirming their effectiveness.

Návaznosti

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

MUNI/A/1608/2020, interní kód MU

Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

MUNI/IGA/1543/2020, interní kód MU

Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)

Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic

Citovat

RIAD, Abanoub, Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER, Yossef MANSY, Islam KASSEM, Amira Bisher KASSEM, Hans-Peter HOWALDT, Miloslav KLUGAR a Sameh ATTIA. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. Journal of Fungi. Basel: MDPI, 2021, roč. 7, č. 10, s. 1-23. ISSN 2309-608X. Dostupné z: https://dx.doi.org/10.3390/jof7100837.

@article{1796259,
   author = {Riad, Abanoub and Shabaan, Alshaimaa Ahmed and Issa, Julien and Ibrahim, Sally and Amer, Hatem and Mansy, Yossef and Kassem, Islam and Kassem, Amira Bisher and Howaldt, HansandPeter and Klugar, Miloslav and Attia, Sameh},
   article_location = {Basel},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/jof7100837},
   keywords = {co-infection; COVID-19; cross-infection; Mucorales; mucormycosis; mycoses; review; Rhizopus; risk factors; steroids},
   language = {eng},
   issn = {2309-608X},
   journal = {Journal of Fungi},
   title = {COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors},
   url = {https://www.mdpi.com/2309-608X/7/10/837},
   volume = {7},
   year = {2021}
}

TY  - JOUR
ID  - 1796259
AU  - Riad, Abanoub - Shabaan, Alshaimaa Ahmed - Issa, Julien - Ibrahim, Sally - Amer, Hatem - Mansy, Yossef - Kassem, Islam - Kassem, Amira Bisher - Howaldt, Hans-Peter - Klugar, Miloslav - Attia, Sameh
PY  - 2021
TI  - COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors
JF  - Journal of Fungi
VL  - 7
IS  - 10
SP  - 1-23
EP  - 1-23
PB  - MDPI
SN  - 2309608X
KW  - co-infection
KW  - COVID-19
KW  - cross-infection
KW  - Mucorales
KW  - mucormycosis
KW  - mycoses
KW  - review
KW  - Rhizopus
KW  - risk factors
KW  - steroids
UR  - https://www.mdpi.com/2309-608X/7/10/837
N2  - Background: Since the novel coronavirus disease (COVID-19) outbreak, the cases of COVID-19 co-infections have been increasingly reported worldwide. Mucormycosis, an opportunistic fungal infection caused by members of the Mucorales order, had been frequently isolated in severely and critically ill COVID-19 patients. Methods: Initially, the anamnestic, clinical, and paraclinical features of seven COVID-19-associated mucormycosis (CAM) cases from Egypt were thoroughly reported. Subsequently, an extensive review of the literature was carried out to describe the characteristics of CAM cases globally, aiming to explore the potential risk factors of mortality in CAM patients. Results: Out of the seven reported patients in the case series, five (71.4%) were males, six (85.7%) had diabetes mellitus, and three (42.9%) had cardiovascular disease. All patients exhibited various forms of facial deformities under the computed tomography scanning, and two of them tested positive for Mucorales using the polymerase chain reaction (PCR) testing. Liposomal amphotericin B (LAmB) was prescribed to all cases, and none of them died until the end of the follow-up. On reviewing the literature, 191 cases were reported worldwide, of which 74.4% were males, 83.2% were from low-middle income countries, and 51.4% were aged 55 years old or below. Diabetes mellitus (79.1%), chronic hypertension (30%), and renal disease/failure (13.6%) were the most common medical comorbidities, while steroids (64.5%) were the most frequently prescribed medication for COVID-19, followed by Remdesivir (18.2%), antibiotics (12.7%), and Tocilizumab (5.5%). Conclusions: As the majority of the included studies were observational studies, the obtained evidence needs to be interpreted carefully. Diabetes, steroids, and Remdesivir were not associated with increased mortality risk, thus confirming that steroids used to manage severe and critical COVID-19 patients should not be discontinued. Lung involvement, bilateral manifestation, and Rhizopus isolation were associated with increased mortality risk, thus confirming that proactive screening is imperative, especially for critically ill patients. Finally, surgical management and antimycotic medications, e.g., amphotericin B and posaconazole, were associated with decreased mortality risk, thus confirming their effectiveness.
ER  -

RIAD, Abanoub, Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER, Yossef MANSY, Islam KASSEM, Amira Bisher KASSEM, Hans-Peter HOWALDT, Miloslav KLUGAR a Sameh ATTIA. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. \textit{Journal of Fungi}. Basel: MDPI, 2021, roč.~7, č.~10, s.~1-23. ISSN~2309-608X. Dostupné z: https://dx.doi.org/10.3390/jof7100837.

Podrobný výpis o publikaci